The global non-hyaluronic acid dermal filler market size is expected to reach USD 520.4 Million by 2032. As per FMI Analysts, the global non-hyaluronic acid dermal filler market is estimated to be valued at USD 392.7 Million in 2022 and is projected to increase at a CAGR of 2.6% from 2022 to 2032.
Report Attribute | Details |
---|---|
Non-Hyaluronic Acid Dermal Filler Market Estimated Base Year Value (2021) | USD 382.75 Million |
Non-Hyaluronic Acid Dermal Filler Market Expected Market Value (2022) | USD 392.7 Million |
Non-Hyaluronic Acid Dermal Filler Market Anticipated Forecast Value (2032) | USD 520.4 Million |
Non-Hyaluronic Acid Dermal Filler Market Projected Growth Rate (2022 to 2032) | 2.6% CAGR |
In recent years, cosmetic plastic surgery has become more popular as it helps to restore a youthful appearance, which includes both surgical and nonsurgical procedures that enhance and reshape structures of the body to improve appearance and confidence.
The market has introduced several advanced aesthetic procedures that are non-invasive or minimally invasive to achieve a youthful appearance for the face and neck area. They include non-hyaluronic acid dermal fillers that are used to retain skin elasticity and maintain a youthful appearance.
The new generation of fillers performs a stimulatory effect, inducing collagen fibers in a focal area of the face, which increases the volume. They are composed of calcium hydroxylapatite, polyalkylimide, polylactic acid, and polymethyl-methacrylate microspheres (PMMA).
Among the primary factors driving the demand for non-hyaluronic acid dermal fillers are the increasing demand for surgical-medical cosmetic procedures, changing demand patterns for less painful treatments among consumers, and increased availability of non-hyaluronic acid dermal fillers by the market share leader.
Increasing advertising in glossy magazines and hoardings by leading manufacturers and distributors will raise public awareness of aesthetic products, thereby helping the market for non-hyaluronic acid dermal fillers to grow.
It is important to note that the primary factors hampering the growth of non-hyaluronic acid dermal fillers market are incorrect training of professionals as well as the high cost of physician services for a procedure. Furthermore, reimbursement options for minimally invasive treatments and procedures are unavailable, which also hampers the growth of the non-hyaluronic acid dermal fillers market.
Regional and local market players are forming strategic partnerships with international players in key target countries such as Japan, South Korea, Thailand, Singapore, and UAE to enhance sales of non-hyaluronic acid dermal filler and collaborating with leading international players in key target countries such as Japan, South Korea, Thailand, Singapore, and UAE to advance commercial presence.
Because less hyaluronic acid is used in non-hyaluronic-based dermal fillers, North America dominates the non-hyaluronic acid dermal fillers market with a 49.2% share.
An IDE clinical trial conducted by Silk Medical Aesthetics and Evolved by Nature for its all-natural dermal filler for nasolabial folds (NLFs) demonstrated positive results in November 2021 with 44 patients.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The non-hyaluronic acid dermal filler market has received a lot of traction in the industry.
Increasing demand for surgical and medical cosmetic procedures, changing consumer preferences for less painful treatments, the preference of dermatologists for non-surgical treatments, and increased offerings for non-hyaluronic acid dermal fillers by the market leader are all factors driving demand for non-hyaluronic acid dermal fillers.
It is anticipated that greater advertising will be done in glossy magazines and hoardings by top manufacturers and distributors, encouraging people to become aware of aesthetic products and ultimately boosting the market for non-hyaluronic acid dermal fillers.
Nonetheless, improper training of professionals for non-hyaluronic acid dermal filler procedures and high physician services costs are factors inhibiting the growth of non-hyaluronic acid dermal fillers. In addition, reimbursement options are missing for minimally invasive treatments and procedures, which further hampers demand for non-hyaluronic acid dermal fillers.
The market size of non-hyaluronic acid dermal fillers is classified geographically into seven key regions, including North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan, the Middle East, and Africa.
In North America, non-hyaluronic acid dermal fillers hold a 49.2% market value share because of increasing procedures associated with non-hyaluronic-based dermal fillers.
With continuous product launches by regional players, Western Europe is expected to account for the second-largest market value share at 22.8%.
Due to medical tourism for aesthetic procedures in ASEAN countries, APEJ can be seen as the fastest-growing region in terms of demand for non-hyaluronic acid dermal fillers, while MEA and Latin America hold the smallest market share by value due to shortages of skilled professionals.
How is the Start-up Ecosystem in the Non-Hyaluronic Acid Dermal Filler Market?
A successful FDA approval for Galderma's Restylane Kysse was received in May 2020. The product is approved for adults over 21 with indications of lip enhancement and correction of upper perioral rhytides (wrinkles around the top of the lips).
It was announced in November 2021 that Silk Medical Aesthetics and Evolved by Nature had completed a feasibility study for their all-natural dermal filler for nasolabial folds (NLFs) that had received FDA approval under the Investigational Device Exemption (IDE).
Some of the leading companies operating in the global non-hyaluronic acid dermal filler market include Allergan, Inc. Galderma SA, Merz Pharma GmbH & Co. KGaA, Suneva Medical Inc., Specialty European Pharma, Sinclair Pharma, Valeant Pharmaceuticals International Inc., LifeCell Corporation, Dr. Korman Laboratories Ltd., ForeverInject International Holdings Co. Limited.
For the promotion and marketing of non-hyaluronic acid dermal fillers, leading manufacturers are focusing on co-promotions and co-marketing strategies, forming strategic partnerships with international players in key target countries like Japan, South Korea, Thailand, Singapore, and UAE, and forming expansionary distribution agreements with dermatologists.
An FDA-approved Investigational Device Exemption (IDE) clinical trial of Silk Medical Aesthetics' all-natural dermal filler for nasolabial folds (NLFs) was conducted in November 2021 with Silver Medical Aesthetics and Evolved by Nature.
The USA Food and Drug Administration approved Restylane Kysse by Galderma in May 2020, indicated for lip augmentation and to lessen upper perioral rhytides (wrinkles around the lips).
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Report Attribute | Details |
---|---|
Growth Rate | CAGR of 2.6% from 2022 to 2032 |
Base Year for Estimation | 2021 |
Historical Data | 2016 to 2021 |
Forecast Period | 2022 to 2032 |
Quantitative Units | Revenue in USD Million and CAGR from 2022-2032 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
Segments Covered | Product Type, Application, Region |
Regions Covered | North America; Latin America; Western Europe; Eastern Europe; Asia-Pacific; Japan; Middle East and Africa |
Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, Russia, Poland, Australia, New Zealand, China, India, Japan, GCC, South Africa, North Africa |
Key Companies Profiled | Allergan, Inc.; Galderma SA; Merz Pharma GmbH & Co.; KGaA, Suneva Medical Inc.; Specialty European Pharma; Sinclair Pharma; Valeant Pharmaceuticals International Inc.; LifeCell Corporation; Dr. Korman Laboratories Ltd.; ForeverInject International Holdings Co. Limited. |
Customization | Available Upon Request |
The global non-hyaluronic acid dermal filler market is set to exceed USD 139.4 Million by 2032.
The USA is projected to lead the non-hyaluronic acid dermal filler market in the forecast period.
The non-hyaluronic acid dermal filler market is likely to secure a CAGR of 2.6% through 2032.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Non-Hyaluronic Acid Dermal Filler Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 5. Global Non-Hyaluronic Acid Dermal Filler Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type 5.1. Collagen 5.2. Hydroxylapatite 5.3. Polylactic Acid 5.4. Polyalkylimide 5.5. Polymethyl-Methacrylate Microspheres 6. Global No-Hyaluronic Acid Dermal Filler Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application 6.1. Aesthetic Volume Restoration 6.2. Wrinkle Reduction 7. Global Non to Hyaluronic Acid Dermal Filler Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. MEA 8. North America Non-Hyaluronic Acid Dermal Filler Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9. Latin America Non-Hyaluronic Acid Dermal Filler Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10. Europe Non- Hyaluronic Acid Dermal Filler Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11. Asia Pacific Non-Hyaluronic Acid Dermal Filler Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12. MEA Non-Hyaluronic Acid Dermal Filler Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13. Key Countries Non-Hyaluronic Acid Dermal Filler Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Allergan, Inc. 15.2. Galderma SA 15.3. Merz Pharma GmbH & Co. KGaA 15.4. KGaA 15.5. Suneva Medical Inc. 15.6. Specialty European Pharma 15.7. Sinclair Pharma 15.8. Valeant Pharmaceuticals International Inc. 15.9. LifeCell Corporation 15.10. Dr. Korman Laboratories Ltd. 15.11. ForeverInject International Holdings Co. Limited 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports